By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics today raised the total offering for its proposed initial public offering to as much as $96.6 million from its original goal of $86.3 million.

In an amended S-1 form filed with the US Securities and Exchange Commission, the Mountain View, Calif., sequencing services firm also reported preliminary earnings for the quarter ended Sept. 30.

For its IPO, Complete Genomics plans to offer 6 million shares at a share price between $12 and $14.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.